Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta superinfection?

References

1. Bichko V., Netter H. J., Wu T. T., Taylor J. 1994; Pathogenesis associated with replication of hepatitis delta virus. Infect Agents Dis 3:94–97[PubMed]
   [Google Scholar]
2. Casey J. L., Brown T. L., Colan E. J., Wignall F. S., Gerin J. L. 1993; A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A 90:9016–9020 [View Article][PubMed]
   [Google Scholar]
3. Hedin G., Weiland O., Ljunggren K., Strömberg A., Nordenfelt E., Hansson B. G., Oberg B. 1987; Treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection with foscarnet. Prog Clin Biol Res 234:309–320[PubMed]
   [Google Scholar]
4. Lau D. T., Doo E., Park Y., Kleiner D. E., Schmid P., Kuhns M. C., Hoofnagle J. H. 1999; Lamivudine for chronic delta hepatitis. Hepatology 30:546–549 [View Article][PubMed]
   [Google Scholar]
5. Le Gal F., Gault E., Ripault M. P., Serpaggi J., Trinchet J. C., Gordien E., Dény P. 2006; Eighth major clade for hepatitis delta virus. Emerg Infect Dis 12:1447–1450 [View Article][PubMed]
   [Google Scholar]
6. Mansour W., Ducancelle A., Le Gal F., Le Guillou-Guillemette H., Abgueguen P., Pivert A., Calès P., Gordien E., Lunel F. 2010; Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol 47:97–99 [View Article][PubMed]
   [Google Scholar]
7. Niro G. A., Ciancio A., Tillman H. L., Lagget M., Olivero A., Perri F., Fontana R., Little N., Campbell F. other authors 2005; Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 22:227–232 [View Article][PubMed]
   [Google Scholar]
8. Niro G. A., Ciancio A., Gaeta G. B., Smedile A., Marrone A., Olivero A., Stanzione M., David E., Brancaccio G. other authors 2006; Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44:713–720 [View Article][PubMed]
   [Google Scholar]
9. Rasshofer R., Choi S., Wölfl P., Manneck K., Weisensee U., Roggendorf M. 1990; Inhibition of HDV RNA replication in vitro by ribavirin and suramin. In Viral Hepatitis and Liver Disease pp. 659–662 Edited by Hollinger F., Lemon S., Margolis H. Baltimore: Williams & Wilkins;
   [Google Scholar]
10. Sheldon J., Ramos B., Toro C., Ríos P., Martínez-Alarcón J., Bottecchia M., Romero M., Garcia-Samaniego J., Soriano V. 2008; Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?. Antivir Ther 13:97–102[PubMed]
    [Google Scholar]
11. Smedile A., Dentico P., Zanetti A., Sagnelli E., Nordenfelt E., Actis G. C., Rizzetto M. 1981; Infection with the delta agent in chronic HBsAg carriers. Gastroenterology 81:992–997[PubMed]
    [Google Scholar]
12. Smedile A., Farci P., Verme G., Caredda F., Cargnel A., Caporaso N., Dentico P., Trepo C., Opolon P. other authors 1982; Influence of delta infection on severity of hepatitis B. Lancet 2:945–947 [View Article][PubMed]
    [Google Scholar]
13. Smedile A., Rosina F., Saracco G., Chiaberge E., Lattore V., Fabiano A., Brunetto M. R., Verme G., Rizzetto M., Bonino F. 1991; Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. Hepatology 13:413–416 [View Article][PubMed]
    [Google Scholar]
14. Tang J. R., Hantz O., Vitvitski L., Lamelin J. P., Parana R., Cova L., Lesbordes J. L., Trépo C. 1993; Discovery of a novel point mutation changing the HDAg expression of a hepatitis delta virus isolate from Central African Republic. J Gen Virol 74:1827–1835 [View Article][PubMed]
    [Google Scholar]
15. Wedemeyer H., Yurdaydìn C., Dalekos G. N., Erhardt A., Çakaloğlu Y., Değertekin H., Gürel S., Zeuzem S., Zachou K. other authors 2011; Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364:322–331 [View Article][PubMed]
    [Google Scholar]
16. Williams V., Brichler S., Radjef N., Lebon P., Goffard A., Hober D., Fagard R., Kremsdorf D., Dény P., Gordien E. 2009; Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol 90:2759–2767 [View Article][PubMed]
    [Google Scholar]
17. Wolters L. M., van Nunen A. B., Honkoop P., Vossen A. C., Niesters H. G., Zondervan P. E., de Man R. A. 2000; Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 7:428–434 [View Article][PubMed]
    [Google Scholar]
18. Yurdaydin C., Bozkaya H., Onder F. O., Sentürk H., Karaaslan H., Akdoğan M., Cetinkaya H., Erden E., Erkan-Esin O. other authors 2008; Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 15:314–321 [View Article][PubMed]
    [Google Scholar]
19. Yurdaydın C., Idilman R., Bozkaya H., Bozdayi A. M. 2010; Natural history and treatment of chronic delta hepatitis. J Viral Hepat 17:749–756 [View Article][PubMed]
    [Google Scholar]